According to the Zhitong Finance App, Xintong Medical-B (02160) announced the results for the year ended December 31, 2023. The group recorded revenue of 336 million yuan, an increase of 33.9% over the previous year. The company's equity shareholders should have accounted for a loss of 472 million yuan, an increase of 3.8%, and a loss of 0.2 yuan per share.
According to the report, the 33.9% increase in revenue was mainly due to the rapid increase in the number of surgeries brought about by the increase in the number of admissions of the Group's TAVI products in China, which increased sales of the Group's TAVI products in China. Meanwhile, in 2023, with the expansion of the Group's TAVI products in overseas markets, the Group's revenue from overseas sales of TAVI products increased by 58.9% over the previous year. As of December 31, 2023, the Group's TAVI products have entered nearly 100 overseas hospitals in Argentina, Colombia, Thailand and Russia.